ATE552273T1 - Verbindungen, die die differenzierung, proliferation, regeneration, plastizität und das überleben von zellen beeinflussen können - Google Patents

Verbindungen, die die differenzierung, proliferation, regeneration, plastizität und das überleben von zellen beeinflussen können

Info

Publication number
ATE552273T1
ATE552273T1 AT02794729T AT02794729T ATE552273T1 AT E552273 T1 ATE552273 T1 AT E552273T1 AT 02794729 T AT02794729 T AT 02794729T AT 02794729 T AT02794729 T AT 02794729T AT E552273 T1 ATE552273 T1 AT E552273T1
Authority
AT
Austria
Prior art keywords
module
survival
cells
compounds
immunoglobulin
Prior art date
Application number
AT02794729T
Other languages
English (en)
Inventor
Vladislav Kiselyov
Galina Skladchikova
Vladimir Berezin
Elisabeth Bock
Original Assignee
Enkam Pharmaceuticals As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enkam Pharmaceuticals As filed Critical Enkam Pharmaceuticals As
Application granted granted Critical
Publication of ATE552273T1 publication Critical patent/ATE552273T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
AT02794729T 2001-08-17 2002-08-19 Verbindungen, die die differenzierung, proliferation, regeneration, plastizität und das überleben von zellen beeinflussen können ATE552273T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200101228 2001-08-17
DKPA200200667 2002-05-02
PCT/DK2002/000541 WO2003016351A2 (en) 2001-08-17 2002-08-19 N - cam related compounds modulating cell groth

Publications (1)

Publication Number Publication Date
ATE552273T1 true ATE552273T1 (de) 2012-04-15

Family

ID=26069061

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02794729T ATE552273T1 (de) 2001-08-17 2002-08-19 Verbindungen, die die differenzierung, proliferation, regeneration, plastizität und das überleben von zellen beeinflussen können

Country Status (6)

Country Link
US (2) US20040242479A1 (de)
EP (1) EP1434798B1 (de)
JP (1) JP4402455B2 (de)
AT (1) ATE552273T1 (de)
CA (1) CA2457164A1 (de)
WO (1) WO2003016351A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1434798B1 (de) 2001-08-17 2012-04-04 Enkam Pharmaceuticals A/S Verbindungen, die die differenzierung, proliferation, regeneration, plastizität und das überleben von zellen beeinflussen können
CA2510715A1 (en) * 2002-12-20 2004-07-08 Enkam Pharmaceuticals A/S Method of modulation of interaction between receptor and ligand
MXPA06001501A (es) * 2003-08-07 2006-09-04 Enkam Pharmaceuticals As Compuestos que comprenden lpa.
US7847058B2 (en) * 2003-09-30 2010-12-07 Elisabeth Bock Method of modulating cell survival, differentiation and/or synaptic plasticity
CN101027320A (zh) * 2004-06-18 2007-08-29 恩卡姆医药公司 Fgfr结合肽
WO2007045243A2 (en) * 2005-10-17 2007-04-26 Enkam Pharmaceuticals A/S Novel fgf receptor binding compounds comprising peptide fragments of neural cell adhesion molecule l1
DK2564864T3 (en) * 2005-11-12 2015-04-07 Trustees Of The Leland Board Of FGF-2 related methods for the diagnosis and treatment of depression
WO2007110079A2 (en) * 2006-03-29 2007-10-04 Enkam Pharmaceuticals A/S Targeted delivery of fgfr ligands into the brain
EP2225272B1 (de) 2007-11-28 2015-10-21 Enkam Pharmaceuticals A/S Aus ncam (fgls) gewonnene peptide
US20110305703A1 (en) * 2008-12-08 2011-12-15 Vegenics Pty Limited Isolated vegf-c and vegf-d peptides and uses thereof
JP2012528083A (ja) * 2009-05-27 2012-11-12 コーベンハブンス ウニベルシテト Ｎｃａｍに結合する線維芽細胞増殖因子レセプター由来ペプチド
DK2854836T3 (en) 2012-06-05 2018-06-18 Univ Leland Stanford Junior NCAM peptide mimetics for use in the treatment of depression
US11220669B2 (en) * 2015-06-05 2022-01-11 Amolifescience Co., Ltd. Defined three dimensional microenvironment for cell culture

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5629291A (en) * 1992-01-31 1997-05-13 La Jolla Cancer Research Foundation Methods of modulating fibronectin extracellular matrix assembly
US5840689A (en) * 1993-10-29 1998-11-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for stimulating the regrowth of neurons
US5693488A (en) * 1994-05-12 1997-12-02 The Rockefeller University Transmembrane tyrosine phosphatase, nucleic acids encoding the same, and methods of use thereof
US6576607B1 (en) * 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
US6313265B1 (en) * 1995-07-24 2001-11-06 The Scripps Research Institute Neurite outgrowth-promoting polypeptides containing fibronectin type III repeats and methods of use
DE69912827T2 (de) 1998-09-29 2004-10-21 Loke Diagnostics Aps Aarhus "ligand presenting assembly" (lpa), verfahren zu dessen herstellung und verwendungen
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
ES2279649T3 (es) 1998-10-23 2007-08-16 Amgen Inc. Compuestos trombopoyeticos.
US7167819B1 (en) * 1999-05-26 2007-01-23 Chiron Corporation Method of determining the three-dimensional shape of a macromolecule
US6749850B1 (en) 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
AU7078200A (en) 1999-08-27 2001-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use
GB0014870D0 (en) * 2000-06-16 2000-08-09 King S College London Peptides
EP1434798B1 (de) 2001-08-17 2012-04-04 Enkam Pharmaceuticals A/S Verbindungen, die die differenzierung, proliferation, regeneration, plastizität und das überleben von zellen beeinflussen können
CA2510715A1 (en) 2002-12-20 2004-07-08 Enkam Pharmaceuticals A/S Method of modulation of interaction between receptor and ligand
MXPA06001501A (es) 2003-08-07 2006-09-04 Enkam Pharmaceuticals As Compuestos que comprenden lpa.

Also Published As

Publication number Publication date
US20040242479A1 (en) 2004-12-02
EP1434798A2 (de) 2004-07-07
WO2003016351B1 (en) 2004-05-06
US20090305951A1 (en) 2009-12-10
JP4402455B2 (ja) 2010-01-20
WO2003016351A2 (en) 2003-02-27
US8071549B2 (en) 2011-12-06
CA2457164A1 (en) 2003-02-27
JP2005510463A (ja) 2005-04-21
WO2003016351A3 (en) 2004-03-25
EP1434798B1 (de) 2012-04-04

Similar Documents

Publication Publication Date Title
ATE552273T1 (de) Verbindungen, die die differenzierung, proliferation, regeneration, plastizität und das überleben von zellen beeinflussen können
BR0016150A (pt) Compostos, composições e métodos para estìmulo de crescimento e alongamento neuronal
ATE382053T1 (de) System zur antikörperexpression und- synthese
WO1996006108A3 (en) Cyclic cs-1 peptidomimetics, compositions and methods of using the same
ATE259828T1 (de) Prosaposin und cytokinabhängige peptide als therapeutisch wirksame mittel
BRPI0513477A (pt) composições e processos de uso de proteìna 4 semelhante a angiotensina
CY1106070T1 (el) Πολυμορφισμοι στο γονιδιο c μεταφορας οργανικου ανιοντος ανθρωπου (oatp-c) - (organic anion transporter c gene)
ATE291011T1 (de) Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
DE69435038D1 (de) Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie
IL195337A0 (en) Cyr61 compositions and methods
AU2003209636A1 (en) Novel chemokine binding peptides capable of modulating the biological activity of chemokines
BR0113820A (pt) Compostos
DE69726884D1 (de) Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
DE69616303D1 (de) O-malonyltyrosyl-verbindungen, o-malonyltyrosyl-verbindungen enthaltende peptide und ihre verwendung
BR9700957A (pt) Proteína de hormónio de crescimento humano mutante deoxiribonucleotídeo peptídeo de uma proteína plasmídeo de expressão produto anticorpo medicamentos para o tratamento de gigantismo e acromegalia e para terapia genética
ATE485377T1 (de) Das überleben dopaminerger neuronen fördernde faktoren und deren verwendungen
ZA200610546B (en) FGFR binding peptides
DE69728415D1 (de) Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2)
BR9811853A (pt) Processos para aumentar o rendimento em plantas
DE69328060D1 (de) Angiotensin-II Typ-1 Rezeptor und dessen Herstellung
ATE431361T1 (de) Verwendung vom transportergen oatp-c zur screening von testsubstanzen
IT1264447B1 (it) Espressione di oncogeni derivati da ntrki in cellule di feocromocitoma pc12 ed utilizzo di questo sistema come screening di sostanze di
WO2009068042A3 (en) Novel peptides derived from ncam (fgls)
Zhang et al. Dimeric β-turn peptidomimetics as ligands for the neurotrophin receptor TrkC
ATE140928T1 (de) Proteine, die die expression von vertebraten-mhc- klasse-ii-genen regulieren, dafür kodierende dna- sequenzen und pharmazeutische zusammensetzungen